Skip to main content
Curiox Biosystems Co., Ltd. logo

Curiox Biosystems Co., Ltd. — Investor Relations & Filings

Ticker · 445680 ISIN · KR7445680002 KO Manufacturing
Open in API
Filings indexed 130 across all filing types
Latest filing 2025-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 445680

About Curiox Biosystems Co., Ltd.

https://www.curiox.com/

Curiox Biosystems is a life science technology company that develops and manufactures automated solutions for cell sample preparation. The company specializes in centrifuge-free technologies designed to standardize and improve workflows for cell analysis. Its core C-FREE™ technology utilizes a gentle, laminar flow-based washing method that replaces traditional centrifugation. This approach minimizes cell stress and loss, thereby enhancing cell retention, viability, and the quality of downstream analytical data. Curiox's product portfolio includes the Pluto series of automated liquid handling workstations and associated consumables. These systems automate critical steps such as cell washing, antibody staining, and antibody cocktailing for applications including flow cytometry, single-cell sequencing, and multiplex immunoassays, supporting research with various sensitive cell types.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standardized disclosure form announcing the receipt and submission of the audit report to the regulatory body, rather than the full, multi-page audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2024
2025-03-18 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Curiox Biosystems. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on financial statements, director appointments, and remuneration limits. While it contains financial data, it is a formal notice for a shareholder meeting rather than an Annual Report (10-K) or an Earnings Release (ER). According to the provided definitions, materials shared for an AGM are classified as AGM-R.
2025-03-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This document details the acquisition of shares by a company executive (Jung, HongTae) of Curiox Biosystems. In the context of financial filings, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2025-02-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their personal share transactions or changes in ownership. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2025-02-24 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting (주주총회소집결의) issued by 큐리옥스바이오시스템즈. It details the date, location, and agenda items (such as financial statement approval, director appointments, and compensation limits) for the upcoming 7th Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2025-02-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Curiox Biosystems regarding a significant change (over 30%) in revenue or profit structure. This is a standard financial disclosure required by the Korea Exchange (KRX) when a company's financial performance deviates significantly from the previous period. It provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change. It is not a full annual report, but rather an initial announcement of financial results/variances, which falls under the Earnings Release (ER) category. FY 2024
2025-02-06 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.